Clinical trials: Metastatic NSCLC - Non-Small Cell Lung Cancer
- Condition Metastatic NSCLC - Non-Small Cell Lung Cancer
- Funder type Industry (pharma, biotech, devices)
Non Small Cell Lung Cancer
Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer
The purpose of this phase 1b/2 study is to estimate the treatment effect of study drug measuring progression free survival.
- Trial name
- NCT01666977
- Testing
- AMG 386, Pemetrexed, Carboplatin
- Where
- 35 sites in United States, Australia and 4 more
- Volunteers
- 36 people
- Sponsor
- Amgen
Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer
Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m
The primary objective of the study is to collect epidemiological data on EGFR mutation status (M+, M-) in a population of predominantly Caucasian ethnicity and to correlate EGFR mutation status with clinico-pathological…
- Trial name
- REASON (NCT00997230)
- Where
- 118 sites in Germany
- Volunteers
- 4,243 people
- Sponsor
- AstraZeneca
Malignant Neoplasm
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Researchers want to learn if using a study medicine called MK-1084 can help treat Non-Small Cell Lung Cancer (NSCLC). MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog…
- Trial name
- NCT07252739
- Testing
- MK-1084, Pembrolizumab, Cetuximab
- Where
- 39 sites in United States, Chile and 11 more
- Volunteers
- 140 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study
In this China extension study, carboplatin and paclitaxel with or without pembrolizumab (MK-3475, KEYTRUDA®) will be administered to Chinese adults with first line metastatic squamous non-small cell lung cancer (NSCLC).
- Trial name
- NCT03875092
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 125 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer
A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
This is a multicenter, randomized, open-label, phase III clinical study, to evaluate the efficacy and safety of IN10018 in combination with D-1553 as compared to anti-PD-1 monoclonal antibody (mAb) in combination with platinum…
- Trial name
- NCT07174908
- Testing
- IN10018 in combination with D-1553, anti-PD-1 monoclonal antibody in combination with platinum and pemetrexed
- Where
- 11 sites in China
- Volunteers
- 400 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Lung Cancer
Carboplatin and Paclitaxel With or Without ISIS 3521 in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. ISIS 3521 may help kill more cancer cells by making tumor cells more sensitive to chemotherapy.
- Trial name
- NCT00017407
- Testing
- ISIS 3521, carboplatin, paclitaxel
- Where
- 2 sites in United States
- Sponsor
- Ionis Pharmaceuticals, Inc.
Advanced Solid Tumors, Metastatic Solid Tumors
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors…
- Conditions
- Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC
- Trial name
- NCT07397338
- Testing
- Daraxonrasib, Elironrasib, Zoldonrasib
- Where
- 19 sites in United States
- Volunteers
- 370 people
- Sponsor
- Revolution Medicines, Inc.
Metastatic Non-Squamous Non-Small Cell Lung Cancer
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or…
- Trial name
- SAPPHIRE (NCT03906071)
- Testing
- Nivolumab, Sitravatinib, Docetaxel
- Where
- 261 sites in United States, Belgium and 10 more
- Volunteers
- 577 people
- Sponsor
- Mirati Therapeutics Inc.
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with select advanced or metastatic solid tumors.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- EXCEED (NCT06238479)
- Testing
- LY4101174
- Where
- 28 sites in United States, Australia and 5 more
- Volunteers
- 490 people
- Sponsor
- Eli Lilly and Company
Advanced Cancer, Metastatic Cancer
A Study of LY3023414 in Participants With Advanced Cancer
The purpose of this study is to find a recommended dose level and schedule of dosing LY3023414 that can safely be taken by participants with advanced or metastatic cancer.
- Conditions
- Advanced Cancer, Metastatic Cancer, Non-Hodgkin's Lymphoma, Metastatic Breast Cancer
- Trial name
- NCT01655225
- Testing
- LY3023414, Midazolam, Fulvestrant
- Where
- 8 sites in United States, Italy and 1 more
- Volunteers
- 156 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
This study seeks to establish the recommended Phase 2 dose (RPTD) of veliparib in combination with nivolumab and platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed) (Phase 1 portion) and to assess…
- Trial name
- NCT02944396
- Testing
- pemetrexed, nivolumab, paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- AbbVie
Thyroid Cancer, Renal Cell Carcinoma
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
A multicenter open-label phase 1/1b study to evaluate the safety and preliminary efficacy of nanrilkefusp alfa as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
- Conditions
- Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer
- Trial name
- NCT04234113
- Testing
- Nanrilkefusp alfa, Pembrolizumab
- Where
- 12 sites in United States, Czechia and 2 more
- Volunteers
- 115 people
- Sponsor
- SOTIO Biotech AG
Non-small Cell Lung Cancer
A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC
This study was a randomized, controlled, open-label, multicenter phase III clinical study to compare the efficacy and safety of SHR-A2009 with platinum-based dual-agent chemotherapy in patients with EGFR-mutated advanced or…
- Trial name
- NCT06671379
- Testing
- SHR-A2009 monotherapy, platinum-based dual-agent chemotherapy
- Where
- China
- Volunteers
- 498 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Metastatic NSCLC
A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
The purpose of this study is to investigate the efficacy, safety, and immunogenicity of GME751 compared with Keytruda® (pembrolizumab) in participants with untreated metastatic non-squamous NSCLC (irrespective of PD-L1 status)…
- Trial name
- NCT06159790
- Testing
- GME751, Keytruda-EU
- Where
- 62 sites in United States, Bosnia and Herzegovina and 14 more
- Volunteers
- 218 people
- Sponsor
- Sandoz
Non-Small Cell Lung Cancer
Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients
This is a Phase 1/2, multi-center, open-label, dose-escalation trial of Ad-MAGEA3 and MG1-MAGEA3 in combination with pembrolizumab in patients with Non-Small Cell Lung Cancer who have completed a first standard therapy with at…
- Trial name
- NCT02879760
- Testing
- Ad-MAGEA3, MG1-MAGEA3, Pembrolizumab
- Where
- 6 sites in Canada
- Volunteers
- 16 people
- Sponsor
- Turnstone Biologics, Corp.
Non Small Cell Lung Cancer, c-MET
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung.
- Trial name
- NCT04928846
- Testing
- Telisotuzumab Vedotin, Docetaxel
- Where
- 317 sites in United States, Argentina and 30 more
- Volunteers
- 768 people
- Sponsor
- AbbVie
PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or…
- Conditions
- PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation
- Trial name
- NCT06922591
- Testing
- TNG462, RMC-9805, RMC-6236
- Where
- 18 sites in United States
- Volunteers
- 183 people
- Sponsor
- Tango Therapeutics, Inc.
Non-Small Cell Lung Cancer
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer
The primary objective of this trial is to evaluate the efficacy of trastuzumab deruxtecan in HER2-overexpressing and/or HER2-mutated advanced NSCLC participants.
- Trial name
- DESTINY-Lung01 (NCT03505710)
- Testing
- Trastuzumab deruxtecan
- Where
- 21 sites in United States, France and 3 more
- Volunteers
- 181 people
- Sponsor
- Daiichi Sankyo
Lung Cancer, Non-Small Cell Lung Cancer
Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC)
The purpose of this research study is to evaluate the safety and effectiveness of Neulasta® (pegfilgrastim) in reducing infection when given on the same day versus one day after the completion of chemotherapy (docetaxel and…
- Trial name
- NCT00094822
- Testing
- PI Discretion
- Volunteers
- 90 people
- Sponsor
- Amgen
Carcinoma, Non-Small-Cell Lung
Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer
The trial will be performed to evaluate whether BI 2536 may be effective in the treatment of advanced or metastatic NSCLC of stage IIIB or IV in patients who relapsed after or failed first-line therapy.
- Trial name
- NCT00376623
- Testing
- BI 2536
- Where
- 7 sites in Germany
- Volunteers
- 96 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.